SEC Form 4 · accession 0001209191-15-083969
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Dec 4, 2015
Accepted (ET)
Dec 8, 2015 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 4, 2015 | M | 4,531 | $53.74 | A | 108,995 | D | |
| Common StockF2,F3 | Dec 4, 2015 | S | 2,179 | $123.53 | D | 106,816 | D | |
| Common StockF3,F4 | Dec 4, 2015 | S | 2,252 | $124.36 | D | 104,564 | D | |
| Common Stock | Dec 4, 2015 | S | 100 | $125.17 | D | 104,464 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $53.74 | Dec 4, 2015 | M | 4,531 | D | — | Sep 3, 2022 | Common Stock | 4,531 | 13,594 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $123.53 (range $123.06 to $124.01).
- F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $124.36 (range $124.11 to $124.93).
- F5The option vests in 16 quarterly installments from 09/04/2012.